Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
55–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.
Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.
Have adequate literacy, vision, and hearing for neuropsychological testing at screening.
Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment.
Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.
If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.
You may not be if
Have dementia or significant other neurological disease that can affect cognition.
Have current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.
Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence.
Have a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.
Have a clinically important laboratory test result or other abnormality as determined by investigator, prior to randomization, that could be detrimental to the participant or could compromise the study.
Have any contraindications for magnetic resonance imaging (MRI).
Have a centrally read MRI that does not meets study entry criteria.
Prior or Current Therapies
Have ever had prior treatment with a passive anti-amyloid immunotherapy.
Have received active immunization against Aβ in any other study.
